<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861757</url>
  </required_header>
  <id_info>
    <org_study_id>10487</org_study_id>
    <secondary_id>H6D-MC-LVHB</secondary_id>
    <nct_id>NCT00861757</nct_id>
  </id_info>
  <brief_title>Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia</brief_title>
  <official_title>A Phase 3, Randomized, Double Blind, Placebo and Tamsulosin Controlled, Parallel Design, Multinational Study to Evaluate the Efficacy and Safety of Tadalafil Once a Day Dosing for 12 Weeks in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo and tamsulosin-controlled, parallel design,
      multinational study to evaluate the efficacy and safety of Tadalafil once-a-day dosing for 12
      weeks in Asian men with signs and symptoms of benign prostatic hyperplasia (BPH).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Weeks in International Prostate Symptom Score (IPSS) Subscore (Storage [Irritative] and Voiding [Obstructive])</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (few obstructive symptoms) to 5 (frequent obstructive symptoms); 4 questions of the obstructive score range from 0 to 20. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); 3 questions of the irritative subscore range from 0 to 15. Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) at 12 Weeks</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Assessment of QoL by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).
Least Squares Mean values were controlled for Benign Prostatic Hyperplasia severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Benign Prostatic Hyperplasia (PBH) Impact Index (BII) at 12 Weeks</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least Squares Mean values were controlled for BPH severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12 Weeks</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Qmax: defined as the peak urine flow rate (measured in milliliters per second [mL/second] using standard calibrated flowmeter).
Least Squares Mean values were controlled for Benign Prostatic Hyperplasia (BPH) severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The PGI-I measures the patient's perception of improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinician Global Impression of Improvement (CGI-I) at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>The CGI-I measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Prostate Specific Antigen (PSA) at 12 Weeks</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>Nanograms of PSA per milliliter (ng/mL) of blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks</measure>
    <time_frame>baseline, 12 weeks</time_frame>
    <description>The PVR is defined as the volume of urine remaining in the bladder after voiding, estimated by ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure (Sitting) at 12 Weeks</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure (Standing) at 12 Weeks</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sitting Heart Rate (HR) at 12 Weeks</measure>
    <time_frame>baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">612</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5 mg Tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5.0 mg Tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>0.2 mg Tamsulosin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
    <arm_group_label>2.5 mg Tadalafil</arm_group_label>
    <arm_group_label>5.0 mg Tadalafil</arm_group_label>
    <other_name>LY450190, Cialis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PO, QD (30 min after meal) for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamsulosin</intervention_name>
    <description>PO, QD (30 min after meal) for 12 weeks</description>
    <arm_group_label>0.2 mg Tamsulosin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asian males, with benign prostatic hyperplasia (BPH) for at least 6 months prior to
             initiation and IPSS score greater than or equal to 13 at the beginning of the
             treatment

          -  Agree not to use any other approved or experimental pharmacologic BPH, erectile
             dysfunction (ED) and overactive bladder (OAB) treatments at any time during the study.

          -  Have not taken Finasteride or Dutasteride therapy, Anti-androgenic hormone or any
             other BPH therapy, ED or OAB therapy for specified duration of time prior to the
             beginning of the treatment

        Exclusion Criteria:

          -  Prostate specific antigen (PSA) score beyond acceptable range defined for study at
             initiation

          -  History of urinary retention or lower urinary tract (bladder) stones within 6 months
             of initiation

          -  History of urinary urethral obstruction due to stricture, valves, sclerosis, or tumor
             at initiation

          -  Clinical evidence of prostate cancer at initiation

          -  Clinical evidence of any of the bladder or urinary tract conditions, which may affect
             lower urinary tract symptom at initiation

          -  History of cardiac conditions, including Angina requiring certain treatment with
             nitrates, unstable angina defined for study, positive cardiac stress test before
             starting the study

          -  History of significant central nervous system injuries (including stroke or spinal
             cord injury within 6 months of initiation)

          -  Use of any nitrates, cancer chemotherapy, androgens, antiandrogens, estrogens,
             luteinizing hormone-releasing hormone (LHRH)agonists/antagonists, or anabolic steroids
             at initiation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>663-8006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>565-0854</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>130-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tao-Yuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <results_first_submitted>May 10, 2011</results_first_submitted>
  <results_first_submitted_qc>May 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 13, 2011</results_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Signs and Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>2.5 mg Tadalafil</title>
          <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>5.0 mg Tadalafil</title>
          <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>0.2 mg Tamsulosin</title>
          <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="151"/>
                <participants group_id="P3" count="155"/>
                <participants group_id="P4" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="136"/>
                <participants group_id="P3" count="137"/>
                <participants group_id="P4" count="143"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>2.5 mg Tadalafil</title>
          <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>5.0 mg Tadalafil</title>
          <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>0.2 mg Tamsulosin</title>
          <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
            <count group_id="B2" value="151"/>
            <count group_id="B3" value="155"/>
            <count group_id="B4" value="152"/>
            <count group_id="B5" value="612"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="8.1"/>
                    <measurement group_id="B2" value="63.7" spread="7.2"/>
                    <measurement group_id="B3" value="62.3" spread="8.0"/>
                    <measurement group_id="B4" value="62.6" spread="7.9"/>
                    <measurement group_id="B5" value="63.1" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="155"/>
                    <measurement group_id="B4" value="152"/>
                    <measurement group_id="B5" value="612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="155"/>
                    <measurement group_id="B4" value="152"/>
                    <measurement group_id="B5" value="612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="85"/>
                    <measurement group_id="B5" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Body mass index is an estimate of body fat based on body weight divided by height squared.</description>
          <units>kilograms/square meters (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.3" spread="2.9"/>
                    <measurement group_id="B2" value="23.9" spread="2.8"/>
                    <measurement group_id="B3" value="24.2" spread="2.8"/>
                    <measurement group_id="B4" value="24.4" spread="2.9"/>
                    <measurement group_id="B5" value="24.2" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Tobacco Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="129"/>
                    <measurement group_id="B5" value="496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Alcohol Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Benign Prostatic Hyperplasia (BPH) Severity</title>
          <description>The International Prostate Symptom Score (IPSS) Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Moderate (IPSS&lt;20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe (IPSS&gt;=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of BPH</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.7" spread="3.4"/>
                    <measurement group_id="B2" value="3.7" spread="3.3"/>
                    <measurement group_id="B3" value="3.5" spread="2.9"/>
                    <measurement group_id="B4" value="3.7" spread="3.2"/>
                    <measurement group_id="B5" value="3.7" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient Global Impressions of Severity Scale (PGI-S)</title>
          <description>The Patient Global Impressions of Severity Scale (PGI-S) measures patient's perception of severity of illness prior to clinical assessments during study visits. Scores range from 1 (Normal) to 4 (Severe) where 1=Normal, 2=Mild, 3=Moderate, and 4=Severe.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impressions of Severity Scale (CGI-S)</title>
          <description>The Clinical Global Impressions of Severity Scale (CGI-S) measures clinician's perception of severity of illness prior to assessments during study visits. Scores range from 1 (Normal) to 4 (Severe) where 1=Normal, 2=Mild, 3=Moderate, and 4=Severe.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="92"/>
                    <measurement group_id="B5" value="371"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Alpha-Blocker Therapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous BPH Therapy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="119"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="493"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Postvoid Residual Volume (PVR)</title>
          <description>Postvoid residual volume (PVR) is defined as the volume of urine remaining in the bladder after voiding, estimated by ultrasound.</description>
          <units>milliliters (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.9" spread="47.7"/>
                    <measurement group_id="B2" value="37.7" spread="40.3"/>
                    <measurement group_id="B3" value="38.4" spread="51.2"/>
                    <measurement group_id="B4" value="32.7" spread="37.1"/>
                    <measurement group_id="B5" value="37.7" spread="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate Volume</title>
          <description>Prostate volume is defined as the volume of prostate estimated by transabdominal or transrectal ultrasound.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" spread="14.0"/>
                    <measurement group_id="B2" value="35.3" spread="16.1"/>
                    <measurement group_id="B3" value="34.8" spread="13.7"/>
                    <measurement group_id="B4" value="33.9" spread="11.1"/>
                    <measurement group_id="B5" value="34.8" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks</title>
        <description>The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.</description>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug: Placebo PO, QD (30min after meal) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30min after meal) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>5 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30min after meal) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg Tamsulosin</title>
            <description>Drug: Tamsulosin PO, QD (30min after meal) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Prostate Symptom Score (IPSS) at 12 Weeks</title>
          <description>The IPSS Total Score is obtained by combining the scores of the responses to 1 through 7 component questions. Each question is scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms.
Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.</description>
          <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="0.4"/>
                    <measurement group_id="O2" value="-4.8" spread="0.4"/>
                    <measurement group_id="O3" value="-4.7" spread="0.4"/>
                    <measurement group_id="O4" value="-5.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>-1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Weeks in International Prostate Symptom Score (IPSS) Subscore (Storage [Irritative] and Voiding [Obstructive])</title>
        <description>IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (few obstructive symptoms) to 5 (frequent obstructive symptoms); 4 questions of the obstructive score range from 0 to 20. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); 3 questions of the irritative subscore range from 0 to 15. Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.</description>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>5.0 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg Tamsulosin</title>
            <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Weeks in International Prostate Symptom Score (IPSS) Subscore (Storage [Irritative] and Voiding [Obstructive])</title>
          <description>IPSS obstructive subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores range from 0 (few obstructive symptoms) to 5 (frequent obstructive symptoms); 4 questions of the obstructive score range from 0 to 20. IPSS irritative subscore is the sum of Questions 2, 4 and 7 of IPSS questionnaire. Scores range from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); 3 questions of the irritative subscore range from 0 to 15. Least Squares Mean values were controlled for prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.</description>
          <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Voiding (Obstructive) Score (N = 154,151,155,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.3"/>
                    <measurement group_id="O2" value="-3.3" spread="0.3"/>
                    <measurement group_id="O3" value="-3.0" spread="0.3"/>
                    <measurement group_id="O4" value="-3.8" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Storage (Irritative) Score (N = 154,151,155,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.2"/>
                    <measurement group_id="O2" value="-1.5" spread="0.2"/>
                    <measurement group_id="O3" value="-1.7" spread="0.2"/>
                    <measurement group_id="O4" value="-1.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This is the p value for the Voiding (Obstructive) Score.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>This is the p value for the Voiding (Obstructive) Score.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>This is the p value for the Voiding (Obstructive) Score.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.072</p_value>
            <p_value_desc>This is the p value for the Storage (Irritative) Score.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>This is the p value for the Storage (Irritative) Score.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>This is the p value for the Storage (Irritative) Score.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) at 12 Weeks</title>
        <description>Assessment of QoL by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).
Least Squares Mean values were controlled for Benign Prostatic Hyperplasia severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.</description>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>5.0 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg Tamsulosin</title>
            <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) at 12 Weeks</title>
          <description>Assessment of QoL by urinary symptoms, with scores ranging from 0 (delighted) to 6 (terrible).
Least Squares Mean values were controlled for Benign Prostatic Hyperplasia severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.</description>
          <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.1"/>
                    <measurement group_id="O2" value="-0.8" spread="0.1"/>
                    <measurement group_id="O3" value="-0.8" spread="0.1"/>
                    <measurement group_id="O4" value="-1.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.013</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Benign Prostatic Hyperplasia (PBH) Impact Index (BII) at 12 Weeks</title>
        <description>The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least Squares Mean values were controlled for BPH severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.</description>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>5.0 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg Tamsulosin</title>
            <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Benign Prostatic Hyperplasia (PBH) Impact Index (BII) at 12 Weeks</title>
          <description>The BII is a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores range from 0 to 13; higher scores represent increased perceived impact of benign prostatic hyperplasia-lower urinary tract symptoms on overall health. Least Squares Mean values were controlled for BPH severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan) and baseline value.</description>
          <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.2"/>
                    <measurement group_id="O2" value="-1.1" spread="0.2"/>
                    <measurement group_id="O3" value="-1.0" spread="0.2"/>
                    <measurement group_id="O4" value="-1.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.201</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.393</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12 Weeks</title>
        <description>Qmax: defined as the peak urine flow rate (measured in milliliters per second [mL/second] using standard calibrated flowmeter).
Least Squares Mean values were controlled for Benign Prostatic Hyperplasia (BPH) severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.</description>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>5.0 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg Tamsulosin</title>
            <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Uroflowmetry Parameter: Peak Flow Rate (Qmax) at 12 Weeks</title>
          <description>Qmax: defined as the peak urine flow rate (measured in milliliters per second [mL/second] using standard calibrated flowmeter).
Least Squares Mean values were controlled for Benign Prostatic Hyperplasia (BPH) severity (moderate/severe), prior alpha blocker use (yes/no), country (Japan/Korea/Taiwan), and baseline value.</description>
          <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
          <units>milliliter per second (mL/sec)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="148"/>
                <count group_id="O4" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="0.4"/>
                    <measurement group_id="O2" value="1.6" spread="0.4"/>
                    <measurement group_id="O3" value="1.3" spread="0.4"/>
                    <measurement group_id="O4" value="2.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.331</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.140</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.940</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Impression of Improvement (PGI-I) at Week 12</title>
        <description>The PGI-I measures the patient's perception of improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).</description>
        <time_frame>12 weeks</time_frame>
        <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>5.0 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg Tamsulosin</title>
            <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Impression of Improvement (PGI-I) at Week 12</title>
          <description>The PGI-I measures the patient's perception of improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).</description>
          <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Little Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Little Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Much Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value came from the Cochran-Mantel-Haenszel test to assess if there was any association between treatment (that is, placebo vs 2.5 mg Tadalafil) and 7 categories of the PGI-I.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value came from the Cochran-Mantel-Haenszel test to assess if there was any association between treatment (that is, placebo vs 5.0 mg Tadalafil) and 7 categories of the PGI-I.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The p-value came from the Cochran-Mantel-Haenszel test to assess if there was any association between treatment (placebo vs 0.2 mg Tamsulosin) and 7 categories of the PGI-I.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinician Global Impression of Improvement (CGI-I) at Week 12</title>
        <description>The CGI-I measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).</description>
        <time_frame>12 weeks</time_frame>
        <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>5.0 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg Tamsulosin</title>
            <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Clinician Global Impression of Improvement (CGI-I) at Week 12</title>
          <description>The CGI-I measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. There are 7 categories with scores ranging from 1 (very much better) to 7 (very much worse). The data are presented as the number of participants in each of the 7 categories: very much better (1); much better (2); a little better (3); no change (4); a little worse (5); much worse (6); very much worse (7).</description>
          <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="155"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Very Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Little Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A Little Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Much Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="48"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very Much Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.034</p_value>
            <p_value_desc>The p-value came from the Cochran-Mantel-Haenszel test to assess if there was any association between treatment (that is, placebo vs 2.5 mg Tadalafil) and 7 categories of the CGI-I.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>The p-value came from the Cochran-Mantel-Haenszel test to assess if there was any association between treatment (that is, placebo vs 5.0 mg Tadalafil) and 7 categories of the CGI-I.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>The p-value came from the Cochran-Mantel-Haenszel test to assess if there was any association between treatment (that is, placebo vs 0.2 mg Tamsulosin) and 7 categories of the CGI-I.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Prostate Specific Antigen (PSA) at 12 Weeks</title>
        <description>Nanograms of PSA per milliliter (ng/mL) of blood.</description>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>5.0 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg Tamsulosin</title>
            <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Prostate Specific Antigen (PSA) at 12 Weeks</title>
          <description>Nanograms of PSA per milliliter (ng/mL) of blood.</description>
          <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
          <units>microgram/Liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="148"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.55"/>
                    <measurement group_id="O2" value="0.04" spread="0.54"/>
                    <measurement group_id="O3" value="0.13" spread="0.59"/>
                    <measurement group_id="O4" value="-0.06" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.412</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.083</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.456</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks</title>
        <description>The PVR is defined as the volume of urine remaining in the bladder after voiding, estimated by ultrasound.</description>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>5.0 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg Tamsulosin</title>
            <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks</title>
          <description>The PVR is defined as the volume of urine remaining in the bladder after voiding, estimated by ultrasound.</description>
          <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
          <units>milliliter (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="45.35"/>
                    <measurement group_id="O2" value="-0.09" spread="45.21"/>
                    <measurement group_id="O3" value="-2.90" spread="48.84"/>
                    <measurement group_id="O4" value="-5.67" spread="34.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.688</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.510</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.212</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure (Sitting) at 12 Weeks</title>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>5.0 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg Tamsulosin</title>
            <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure (Sitting) at 12 Weeks</title>
          <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="10.9"/>
                    <measurement group_id="O2" value="-2.3" spread="11.0"/>
                    <measurement group_id="O3" value="-0.5" spread="12.4"/>
                    <measurement group_id="O4" value="0.2" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="8.6"/>
                    <measurement group_id="O2" value="-2.5" spread="7.8"/>
                    <measurement group_id="O3" value="-1.4" spread="8.1"/>
                    <measurement group_id="O4" value="-0.6" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>This is the p value for systolic blood pressure.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.274</p_value>
            <p_value_desc>This is the p value for systolic blood pressure.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.538</p_value>
            <p_value_desc>This is the p value for systolic blood pressure.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>This is the p value for diastolic blood pressure.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.216</p_value>
            <p_value_desc>This is the p value for diastolic blood pressure.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.524</p_value>
            <p_value_desc>This is the p value for diastolic blood pressure.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure (Standing) at 12 Weeks</title>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>All efficacy analyses were performed on an intent-to-treat (ITT) basis. The primary analysis population for efficacy was the Full Analysis Set (FAS) which included all subjects who were randomized and started study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>5.0 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg Tamsulosin</title>
            <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure (Standing) at 12 Weeks</title>
          <population>All efficacy analyses were performed on an intent-to-treat (ITT) basis. The primary analysis population for efficacy was the Full Analysis Set (FAS) which included all subjects who were randomized and started study medication.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="11.8"/>
                    <measurement group_id="O2" value="-2.9" spread="12.3"/>
                    <measurement group_id="O3" value="0.6" spread="11.6"/>
                    <measurement group_id="O4" value="-0.9" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="8.1"/>
                    <measurement group_id="O2" value="-2.3" spread="8.0"/>
                    <measurement group_id="O3" value="-1.7" spread="8.2"/>
                    <measurement group_id="O4" value="-1.0" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>This is the p value for systolic blood pressure.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.723</p_value>
            <p_value_desc>This is the p value for systolic blood pressure.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.273</p_value>
            <p_value_desc>This is the p value for systolic blood pressure.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>This is the p value for diastolic blood pressure.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <p_value_desc>This is the p value for diastolic blood pressure.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.278</p_value>
            <p_value_desc>This is the p value for diastolic blood pressure.</p_value_desc>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sitting Heart Rate (HR) at 12 Weeks</title>
        <time_frame>baseline, 12 weeks</time_frame>
        <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>2.5 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>5.0 mg Tadalafil</title>
            <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>0.2 mg Tamsulosin</title>
            <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sitting Heart Rate (HR) at 12 Weeks</title>
          <population>The primary analysis population for efficacy included all subjects who were randomized and started study medication. All efficacy analyses were performed on an intent-to-treat (ITT) basis.</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="151"/>
                <count group_id="O3" value="154"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="8.9"/>
                    <measurement group_id="O2" value="0.7" spread="8.3"/>
                    <measurement group_id="O3" value="0.6" spread="8.3"/>
                    <measurement group_id="O4" value="0.6" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.330</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.838</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.409</p_value>
            <method>Wilcoxon rank-sum test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Drug: Placebo by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>2.5 mg Tadalafil</title>
          <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>5.0 mg Tadalafil</title>
          <description>Drug: Tadalafil PO, QD (30 min after meal) for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>0.2 mg Tamsulosin</title>
          <description>Drug: Tamsulosin PO, QD (30 min after meal) for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="154"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="151"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="155"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Adenoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Transaminases abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Coccydynia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pyogenic granuloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Perineal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Spontaneous penile erection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Colon polypectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="155"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="155"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

